EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Prevention of vertical transmission of hepatitis B: A retrospective review of a 5‐year maternal–infant cohort in London

Elizabeth O'Mahony iD, Sophie Raghunanan, Ashley Brown, Caroline Foster

Journal of Paediatrics and Child Health · 2024

DOI: 10.1111/jpc.16609 ↗

At a glance

Journal article in Journal of Paediatrics and Child Health, 2024. Written by Elizabeth O'Mahony and 3 co-authors. Institution: Oxford Vaccine Group, Department of Paediatrics, University of Oxford University - Medical Sciences, Oxford, United Kingdom. Major MEDLINE topics: Infectious Disease Transmission, Vertical, Hepatitis B. Cited 1 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

The World Health Organization (WHO) estimates that 3.5% of the population live with hepatitis B virus (HBV); migrants to Europe are disproportionately affected. UK birth dose HBV vaccination is limited to infants born to those living with HBV (LWHBV). High‐risk infants (high maternal infectivity, low birthweight) also receive HBV immunoglobulin (HBIG). The Family Hepatitis Clinic follows infants and those LWHBV working towards WHO goals of combating viral hepatitis by 2030.

Methods

A trust‐wide electronic note review of outcomes for infants born to those LWHBV (2016–2020).

Results

Two hundred and eighty‐three infants, 134 (47%) females, born to those LWHBV were referred. Two hundred and thirty‐one (82%) attended follow‐up with a vertical transmission rate of 0%. Twenty (7%) individuals LWHBV received tenofovir disoproxil fumerate in pregnancy; median viral load (VL) at initiation 125 416 376 DNA IU/mL, one having birth VL. Twenty‐eight (10%) infants were stratified as high risk and all received HBIG and birth dose vaccination with 9 (32%) subsequently lost to follow‐up, compared to 48 (19%) low‐risk infants. 267/283 (94%) had birth dose vaccination documented and 206/283 (73%) received at least four vaccine doses. 215/283 (76%) infants had serology by 24 months; 17 (6%) with suboptimal vaccine responses: hepatitis B surface antibody 4 doses, 77% HBsAb >100).

Subjects

MeSH terms (MEDLINE)

Infectious Disease Transmission, VerticalHepatitis BHumansFemaleRetrospective StudiesPregnancyMaleLondonInfantInfant, NewbornHepatitis B VaccinesAdultPregnancy Complications, InfectiousImmunoglobulins

Author keywords

hepatitis Bhepatitis B birth dose vaccinationhepatitis B immunoglobulin (HBIG)tenofovir disoproxil fumerate (TDF)vertical transmission

Substances

Hepatitis B VaccinesImmunoglobulins

Authors and institutions

  • Oxford Vaccine Group, Department of Paediatrics, University of Oxford University - Medical Sciences, Oxford, United Kingdom.
  • Department of Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Department of Hepatology, Imperial College London, Imperial College NIHR BRC, London, United Kingdom.

ORCID profiles: Elizabeth O'Mahony

Cite

APA

O'Mahony, E., Raghunanan, S., Brown, A., & Foster, C. (2024). Prevention of vertical transmission of hepatitis B: A retrospective review of a 5‐year maternal–infant cohort in London. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.16609

Vancouver

O'Mahony E, Raghunanan S, Brown A, Foster C. Prevention of vertical transmission of hepatitis B: A retrospective review of a 5‐year maternal–infant cohort in London. Journal of Paediatrics and Child Health. 2024. doi:10.1111/jpc.16609

BibTeX
@article{OMahony2024,
  author = {O'Mahony, Elizabeth and Raghunanan, Sophie and Brown, Ashley and Foster, Caroline},
  title = {Prevention of vertical transmission of hepatitis B: A retrospective review of a 5‐year maternal–infant cohort in London},
  journal = {Journal of Paediatrics and Child Health},
  year = {2024},
  doi = {10.1111/jpc.16609}
}
Start for free →